ClinicalTrials.gg

Program

CG-7321

A development code.

Its studies are mostly in Breast Neoplasms, led by Chengdu Cynogen Bio-pharmaceutical Tech..

Furthest: phase 1, since Oct 27, 20261 company-led study, 1 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chengdu Cynogen Bio-pharmaceutical Tech.11 open or runningphase 1since Oct 27, 2026Oct 27, 2026Apr 2027phase 1 · NCT07923214

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2026First study: phase 1 study in Breast NeoplasmsFirst studyNCT07923214 · 66 planned · China

Ahead

  1. Apr 2027Primary completion: phase 1 study in Breast NeoplasmsNCT07923214

TargetBeta

CDK2 →CDK4 →read by rule
“CG-7321 is a novel oral small molecule CDK2 inhibitor with balanced CDK4/6/9 inhibition potency, being developed for the treatment of advanced solid tumors, being developed for the treatment of advanced solid tumors.”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
culmerciclibSino Biopharmaceuticalphase 311
vustanaciclibregor-pharmaceuticals-incphase 23
nkt5097 cdk2rulenikang-therapeutics-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07923214Breast Neoplasms · China1RecruitingApr 202766

How it is read

Names in the registry

  • “CG-7321”, 1 entry

Codes read as this program: CG7321.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.